Merck-Eisai endometrial cancer therapy combo fails first-line treatment trial Ruchika Sharma9 Dec 2023 1:30 PM ISTRahway: Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line...
Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients Ruchika Sharma8 Dec 2023 3:19 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating...
Merck KGaA multiple sclerosis drug fails in late-stage trials Ruchika Sharma7 Dec 2023 3:30 PM ISTFrankfurt: Merck KGaA's experimental multiple sclerosis (MS) drug missed the primary goal in highly anticipated late-stage trials, dealing a...
Merck application for Keytruda plus Padcev for Urothelial Cancer gets USFDA priority review Ruchika Sharma2 Dec 2023 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has accepted...
Turkey launches investigation into 19 pharma cos Ruchika Sharma1 Dec 2023 12:49 PM ISTAnkara: Turkey's competition authority said on Thursday it had launched an investigation into 19 pharmaceutical companies to determine whether they...
Merck 21-valent Pneumococcal Conjugate Vaccine demonstrates superior immunogenicity for 10 of 11 Unique Serotypes compared to PCV20 in adults 50 years of age and older Ruchika Sharma30 Nov 2023 1:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced results from STRIDE-3, a Phase 3 trial evaluating V116, the...
Merck to acquire Caraway Therapeutics for up to USD 610 million Ruchika Sharma23 Nov 2023 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. have announced that the companies have...
USFDA staff flags concerns about Merck chronic cough drug Ruchika Sharma16 Nov 2023 1:25 PM ISTStaff assessment of the data submitted by Merck showed a small reduction in cough frequency and side effects such as loss of taste in patients who...
Merck gets positive EMA Committee opinion for Keytruda plus Gemcitabine, Cisplatin for Biliary Tract Cancer Ruchika Sharma14 Nov 2023 2:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the European Medicines Agency's Committee for Medicinal...
Merck, Huma Therapeutics collaborate to develop digital solution for cancer patients Ruchika Sharma12 Nov 2023 11:00 AM ISTLondon: Huma Therapeutics, a global digital health company, and Merck KGaA, Darmstadt, Germany, a science and technology company, have announced...
Merck bags USFDA nod for Keytruda plus gemcitabine, cisplatin to treat Biliary Tract Cancer Ruchika Sharma2 Nov 2023 2:30 PM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
Merck strengthens oncology pipeline through strategic partnership with Hengrui Ruchika Sharma31 Oct 2023 2:28 PM ISTGermany: Merck, a science and technology company, has announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. The...
